<HTML><!-- #BeginTemplate "/Templates/new news.dwt" --><!-- DW6 -->
<head>
<!-- #BeginEditable "doctitle" -->
<TITLE>US Public Interest Research Group </TITLE>
<!-- #EndEditable -->
</head>
<BODY BGCOLOR="#FFFFFF" TEXT="#000000">
<table width="100%" border="0" align="center">
<tr>
<!-- #BeginEditable "Contact" -->  
<td align="left" valign="top" width="200">
<p><font size="2" face="Arial, Helvetica, sans-serif"><b>FOR IMMEDIATE RELEASE</b><br>
MAY 3, 2006<br>
12:00&nbsp;PM<br>

</font></p>
</td>
<td align="left" valign="top" width="340">
<p><font size="2" face="Arial, Helvetica, sans-serif"><b>CONTACT: <a href="http://www.uspirg.org">US Public Interest Research Group</a> <br>
</b>Paul Brown,
(202) 546-9707</font></p>
</td>
<!-- #EndEditable -->
</tr>
<tr>
<td colspan="2">&nbsp;</td>
</tr>

<tr>
<td colspan="2">
<div align="center"><b><font size="4" face="Arial, Helvetica, sans-serif">
<!-- #BeginEditable "Header" -->Deceptive Prescription Drug Marketing Tactics &lsquo;Common and Dangerous&rsquo;<br>
<font size="2">New Report says FDA&rsquo;s Enforcement Policies Ineffective</font><!-- #EndEditable --></font></b></div>
</td>
</tr>
<tr>
<td colspan="2">&nbsp;</td>
</tr>
<tr>
<td colspan="2"><font size="2" face="Arial, Helvetica, sans-serif">
<!-- #BeginEditable "Body" -->
<p>WASHINGTON - May 3 - <font size="2" face="Arial, Helvetica, sans-serif">Prescription drug marketers made deceptive claims to doctors and consumers about 150 different drugs including Vioxx and OxyContin, according to a new report released today by U.S. Public Interest Research Group and the NJPIRG Law and Policy Center.</font>
<p><font size="2" face="Arial, Helvetica, sans-serif">&ldquo;Powerful prescription drugs can improve or save lives, but if they&rsquo;re marketed to the wrong people, they can cripple or even kill,&rdquo; said NJPIRG Law and Policy Center Consumer Advocate Abigail Caplovitz, the report&rsquo;s author. </font></p>
<p><font size="2" face="Arial, Helvetica, sans-serif">The report, &ldquo;<a href="http://uspirg.org/uspirg.asp?id2=24015"><u>Turning Medicine Into Snake Oil: How Drug Marketers Put Patients At Risk</u></a>,&rdquo; analyzes five years of regulatory letters from the FDA to prescription drug companies. The report called false and misleading prescription drug advertising &ldquo;common and dangerous.&rdquo;</font></p>
<p><font size="2" face="Arial, Helvetica, sans-serif"><strong>Among the report&rsquo;s key findings:</strong></font></p>
<p><font size="2" face="Arial, Helvetica, sans-serif"><strong>Drug marketers make unsupported or misleading claims.</strong></font></p>
<p><font size="2" face="Arial, Helvetica, sans-serif">&middot; Thirty-eight percent of messages to doctors and consumers made unsupported or misleading claims.</font></p>
<p><font size="2" face="Arial, Helvetica, sans-serif">&middot; Thirty-five percent misrepresented risks or side effects of taking the drugs.</font></p>
<p><font size="2" face="Arial, Helvetica, sans-serif">&middot; Twenty-two percent promoted unproven drug uses.</font></p>
<p><font size="2" face="Arial, Helvetica, sans-serif"><strong>FDA policies to stop deceptive advertising are ineffective.</strong></font></p>
<p><font size="2" face="Arial, Helvetica, sans-serif">&middot; About one-third of the drug marketers receiving FDA enforcement letters received more than one letter declaring their ads false or misleading.</font></p>
<p><font size="2" face="Arial, Helvetica, sans-serif">&middot; Many drug marketers received more than one letter addressing the same problem.</font></p>
<p><font size="2" face="Arial, Helvetica, sans-serif"><strong>Deceptive marketing aimed at doctors.</strong></font></p>
<p><font size="2" face="Arial, Helvetica, sans-serif">&middot; Physicians were inundated with 38 different types of dangerous and misleading marketing tactics.</font></p>
<p><font size="2" face="Arial, Helvetica, sans-serif">&ldquo;Doctors are targeted because they&rsquo;re the ones who write the prescriptions,&rdquo; said U.S. PIRG Consumer Advocate Paul Brown. &ldquo;Drug companies know who they have to influence, if they want to jack up sales and profits.&rdquo;</font></p>
<p><font size="2" face="Arial, Helvetica, sans-serif"><strong>Deceptive marketing aimed at consumers.</strong></font></p>
<p><font size="2" face="Arial, Helvetica, sans-serif">&middot; Print ads, TV ads and website ads make up almost 80 percent of deceptive marketing aimed at consumers. These direct-to-consumer ads potentially mislead millions of people, far more than the marketing aimed solely at doctors.</font></p>
<p><font size="2" face="Arial, Helvetica, sans-serif"><strong>Deceptive marketing includes clinical trials.</strong></font></p>
<p><font size="2" face="Arial, Helvetica, sans-serif">&middot; Drug companies suppress unfavorable clinical trials.</font></p>
<p><font size="2" face="Arial, Helvetica, sans-serif">&middot; They use public relations firms to write favorable research reports and then list a doctor&rsquo;s name on the report as the &ldquo;author.&rdquo; </font></p>
<p><font size="2" face="Arial, Helvetica, sans-serif">&middot; The FDA highlighted at least 82 times false or misleading advertising cited clinical trials. </font></p>
<p><font size="2" face="Arial, Helvetica, sans-serif">&ldquo;If we can&rsquo;t rely on clinical trial reports, the very foundation of pharmaceutical medicine is destroyed,&rdquo; Caplovitz said. &ldquo;Medicine, not marketing must drive clinical trial designs.&rdquo;</font></p>
<p><font size="2" face="Arial, Helvetica, sans-serif"><strong>The report recommends that Congress:</strong></font></p>
<p><font size="2" face="Arial, Helvetica, sans-serif">&middot; Pass The Food and Drug Administration Safety Act, Senate Bill 930, which requires the FDA to review prescription drug advertising materials before consumers see them.</font></p>
<p><font size="2" face="Arial, Helvetica, sans-serif">&middot; Require that clinical trials used to support advertising claims be approved by the FDA.</font></p>
<p><font size="2" face="Arial, Helvetica, sans-serif">&middot; Authorize the FDA to levy stiff fines against drug marketers who use deceptive tactics.</font></p>
<p><font size="2" face="Arial, Helvetica, sans-serif">&ldquo;The FDA&rsquo;s current enforcement isn&rsquo;t even a slap on the wrist,&rdquo; Brown said. &ldquo;A slap on the wrist would be an improvement.&rdquo;</font></p>
<p><font size="2" face="Arial, Helvetica, sans-serif"><strong>The report recommends that individual states:</strong></font></p>
<p><font size="2" face="Arial, Helvetica, sans-serif">&middot; Pass laws to make it easier for consumer to sue drug marketers for deceptive advertising.</font></p>
<p><font size="2" face="Arial, Helvetica, sans-serif">&middot; Create a comprehensive, searchable database of clinical trials, which would make it harder for drug marketers to suppress or misrepresent data.</font></p>
<p><font size="2" face="Arial, Helvetica, sans-serif">&ldquo;States can protect consumers now from the dangers of deceptive drug marketing,&rdquo; Caplovitz said. &ldquo;There&rsquo;s no need to wait for Congress or the FDA.&rdquo;</font></p>
<p><font size="2" face="Arial, Helvetica, sans-serif">The report includes six case studies of deceptive marketing: Vioxx, OxyContin, Paxil, Accutane, Neurotin and Tindamax. The report&rsquo;s numbers are derived from FDA letters to drug marketers.</font></p>
<!-- #EndEditable -->
<p align="center">###</p></font></td>
</tr>
</table>
</BODY>
<!-- #EndTemplate --></HTML>